Nine‐year data show sustained benefit of nivolumab in patients with high‐risk resected melanoma

nivolumab consistently improved recurrence-free survival (RFS) in patients with resected stage IIIB-C or IV melanoma according to the final 9-year data from CheckMate 238. 1 The data were presented by Paolo A. Ascierto, MD, of the

Authors

Publication Details

Journal
Cancer
Published
2026-02-01
DOI
https://doi.org/10.1002/cncr.70234
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nine‐year data show sustained benefit of nivolumab in patients with high‐risk resected melanoma

Leah Lawrence
Cancer
Cancer Immunotherapy and Biomarkers
article

Nine‐year data show sustained benefit of nivolumab in patients with high‐risk resected melanoma

Leah Lawrence
article en

Abstract

nivolumab consistently improved recurrence-free survival (RFS) in patients with resected stage IIIB-C or IV melanoma according to the final 9-year data from CheckMate 238. 1 The data were presented by Paolo A. Ascierto, MD, of the

CancerVol. 132(3)
Openalex Percentile: Top 66%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Nine‐year data show sustained benefit of nivolumab in patients with high‐risk resected melanoma — Leah Lawrence · Cancer (2026) | TGRS Research Map | TGRS